Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRO1107 |
Synonyms | |
Therapy Description |
PRO1107 is an antibody-drug conjugate (ADC) comprising an anti-PTK7 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against tumor cells and demonstrates antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRO1107 | PRO 1107|PRO-1107 | PRO1107 is an antibody-drug conjugate (ADC) comprising an anti-PTK7 monoclonal antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cytotoxicity against tumor cells and demonstrates antitumor activity (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |